NASDAQ: FHTX - Foghorn Therapeutics Inc.

Altı ay boyunca karlılık: -38.22%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Foghorn Therapeutics Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

daha fazla ayrıntı
It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2020-10-23
ISIN US3441741077
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://foghorntx.com
Цена ао 5.01
Günlük fiyat değişimi: +4.75% (4.63)
Haftalık fiyat değişimi: -7.27% (5.23)
Aylık fiyat değişimi: +21.86% (3.98)
3 ayda fiyat değişimi: -39.3% (7.99)
Altı ayda fiyat değişimi: -38.22% (7.85)
Yıllık fiyat değişimi: -38.92% (7.94)
3 yılda fiyat değişimi: -50.26% (9.75)
5 yılda fiyat değişimi: 0% (4.85)
10 yılda fiyat değişimi: 0% (4.85)
Yılbaşından bu yana fiyat değişimi: +2.75% (4.72)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 8.16 1
P/BV -3.61 0
P/E 0 0
EV/EBITDA -2.45 0
Toplam: 3.88

Yeterlik

İsim Anlam Seviye
ROA, % -34.42 0
ROE, % 127.51 10
Toplam: 3.33

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.4542 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 7843.02 10
karlılık Ebitda, % 109.33 10
karlılık EPS, % 0.2094 1
Toplam: 8
Daha fazla ayrıntı

İşlem tarihi Açıklama tarihi İçeriden bilgi Tip Fiyat Hacim Miktar Şuna kadar paylaş:, % Şu tarihten sonra paylaş:, % Belge
23.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Satış 10.17 8 716 857 0 0 bağlantı
23.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Satın almak 3.72 3 188 857 0 0 bağlantı
20.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Satış 10.04 358 990 35756 0 -0.09 bağlantı
20.09.2024 24.09.2024 Costa Carlos
Chief People Officer		 Satın almak 3.72 133 012 35756 0 0.09 bağlantı
18.09.2024 20.09.2024 Costa Carlos
Chief People Officer		 Satış 10.05 116 319 11574 0 -0.03 bağlantı
18.09.2024 20.09.2024 Costa Carlos
Chief People Officer		 Satın almak 3.72 43 055 11574 0 0.03 bağlantı

Kurumlar Hacim Paylaşmak, %
Flagship Pioneering Inc. 12674120 29.78
FMR, LLC 2810009 6.6
Raymond James & Associates, Inc. 2068387 4.86
Euclidean Capital LLC 1573761 3.7
Blackrock Inc. 1305868 3.07
Vanguard Group Inc 1025113 2.41
Artal Group S.A. 720720 1.69
Point72 Asset Management, L.P. 540000 1.27
Alphabet Inc. 500901 1.18
Geode Capital Management, LLC 448350 1.05

ETF Paylaşmak, % Yıllık karlılık, % Temettüler, %
Range Cancer Therapeutics ETF 2.15956 47.24 0.11955
iShares Micro-Cap ETF 0.06408 17.09 1.54048
iShares Russell 2000 Growth ETF 0.01111 38.04 0.6026
Vanguard Russell 2000 ETF 0.01 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0.01 23.05 0.60264
ProShares UltraPro Russell2000 0.00545 89.82 1.47873
ProShares Hedge Replication ETF 0.00149 5.92 1.47892
Avantis U.S. Equity ETF 0.0004 23.04 1.59151
Vanguard Russell 3000 ETF 0 31.87 1.43817



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Adrian H. B. Gottschalk President, CEO & Director 784.65k 1976 (49 yıllar)
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer 572.6k 1965 (60 yıllar)
Mr. Michael J. LaCascia Chief Legal Officer 565.5k 1965 (60 yıllar)
Dr. Gerald R. Crabtree M.d. Founder & Member of Scientific Advisory Board N/A
Mr. Saurabh Sewak Ph.D. Vice President of Corporate Development N/A
Mr. Carlos Costa Chief People Officer N/A 1973 (52 yıl)
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer 300.16k 1971 (54 yıl)
Ms. Karin Hellsvik VP of Corporate Affairs & Investor Relations N/A
Mr. Kristian Humer M.B.A. Chief Financial Officer N/A 1976 (49 yıllar)
Dr. Anna Rivkin Ph.D. Chief Business Officer

Adres: United States, Cambridge. MA, 500 Technology Square - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://foghorntx.com